Topic

News

News, announcements, and updates from Sanare Lab Science.

35 articles

Long Read

Sanare Lab fenbendazole purity lab test results

Happy Healing Store Is Spreading False Information

A forensic investigation into how Happy Healing Store fabricated 'Spectrix' fenbendazole purity reports to smear competitors while awarding itself an impossible 100%.

13 min read

News

Aug 9, 2026

1,9-Dimethyl Methylene Blue Shows Photodynamic Activity in Oropharyngeal Carcinoma Models

A novel methylene blue derivative, 1,9-dimethyl methylene blue, shows promise as a photosensitizer for photodynamic therapy against oropharyngeal cancer.

⚡ 4 min read Read brief →

Aug 9, 2026

Curcumin Analog E145 Suppresses NF-κB to Inhibit Breast Cancer Growth and Metastasis

A synthetic curcumin analog called E145 shows potent anticancer activity by blocking NF-κB signaling in breast cancer cells and reducing lung metastasis in mice.

⚡ 4 min read Read brief →

Aug 9, 2026

Curcumin Calms Breast Cancer Inflammasome Activation in Tumor-Associated Macrophages

Curcumin suppresses NLRP3 inflammasome activation in tumor-associated macrophages, reducing inflammatory signals that drive breast cancer progression.

⚡ 3 min read Read brief →

Aug 8, 2026

Nitazoxanide Antiparasitic Drug Induces Ferroptosis in TNBC (Redox Reports 2026)

A 2026 preclinical study shows nitazoxanide, an FDA-approved antiparasitic drug, triggers ferroptosis in TNBC cells by disrupting iron homeostasis and degrading the beta-catenin/GPX4 axis. The findings are based on in vitro and zebrafish xenograft data only.

⚡ 4 min read Read brief →

Aug 8, 2026

Curcumin Analogue B-155 Outperforms Natural Curcumin in Ovarian Cancer Preclinical Study (2026)

A 2026 preclinical study found that the synthetic curcumin analogue B-155 demonstrates significantly greater cytotoxicity than natural curcumin in SKOV3 ovarian cancer cells, with effects including G2/M cell-cycle arrest, apoptosis, and p38 MAPK binding. The study is limited to in vitro data.

⚡ 5 min read Read brief →

Aug 8, 2026

Mebendazole Prevents Meningioma Invasion in 3D Patient-Derived Spheroids (2026)

In a 2026 preclinical study using patient-derived 3D spheroids, mebendazole prevented cellular invasion in 89% of meningioma samples by disrupting Rho-GTPase-mediated microtubule function. This is early laboratory evidence, not a clinical trial.

⚡ 5 min read Read brief →

Aug 8, 2026

Curcumin Hydrogel Prevents Postoperative Prostate Cancer Recurrence (2026)

A 2026 preclinical study in the International Journal of Pharmaceutics developed a curcumin-releasing hydrogel that, when applied after prostate cancer surgery, suppressed tumor regrowth and reduced lymph node metastasis by maintaining high local drug concentration. Animal-model evidence only.

⚡ 5 min read Read brief →

Aug 8, 2026

Mebendazole Disrupts Nucleotide Metabolism in Gastric Cancer (2026)

A 2026 preclinical study shows mebendazole impairs nucleotide metabolism enzymes in gastric cancer cells, causing cell cycle arrest and antiproliferative activity comparable to 5-FU with lower toxicity to normal cells. Laboratory evidence only.

⚡ 5 min read Read brief →

Aug 6, 2026

Curcumin Triggers Ferroptosis in Thyroid Cancer via GPX4 Downregulation (2026 Study)

A 2026 preclinical study shows curcumin induces ferroptosis in papillary thyroid cancer cells by downregulating GPX4, suppressing tumour growth in mice without organ toxicity.

⚡ 5 min read Read brief →

Aug 6, 2026

Drug Repurposing for Renal Cell Carcinoma: Ivermectin and Antiparasitics Reviewed (2026)

A July 2026 review evaluates repurposed drugs — including ivermectin and artesunate — against renal cell carcinoma, identifying multiple targetable signalling pathways in preclinical models.

⚡ 5 min read Read brief →

Aug 6, 2026

Antiparasitic Drugs in Stage IV Cancer: 6-Patient Case Series (Integrative Medicine, 2026)

A 2026 case series in Integrative Medicine describes 6 stage IV cancer patients who showed prolonged survival after AMA-guided antiparasitic protocols including ivermectin and mebendazole.

⚡ 5 min read Read brief →

Aug 6, 2026

Ivermectin Inhibits Estrogen Receptor and HER2 Pathways in Endocrine-Resistant Breast Cancer

Researchers at Chulalongkorn University found that ivermectin significantly suppressed estrogen-induced proliferation and downregulated ER, HER2, and TGF-β pathway markers in endocrine-resistant breast cancer cells, suggesting potential as a repurposed agent to overcome hormonal therapy resistance.

⚡ 5 min read Read brief →

Aug 6, 2026

Mebendazole Reprograms Oncogenic Networks Across Multiple Cancer Types

Researchers found that mebendazole at 0.7 µM reprogrammed oncogenic and tumor-suppressor networks across eight cancer cell lines, suppressing ENOX2 and MMP2 while activating RASSF1A by over 200-fold.

⚡ 5 min read Read brief →

Aug 6, 2026

Ivermectin and Metformin Combination Promotes Autophagy in Breast Cancer via PI3K/AKT/mTOR Pathway

Chinese researchers found that combining ivermectin with metformin significantly inhibited MCF-7 breast cancer cell viability, migration, and invasion by suppressing PI3K/AKT/mTOR signaling and triggering autophagy.

⚡ 5 min read Read brief →

Aug 3, 2026

Fenbendazole + Photothermal Therapy Triggers Ferroptosis in Bladder Cancer (Advanced Science, 2026)

A June 2026 study in Advanced Science describes a nanoplatform combining fenbendazole with photothermal therapy to trigger ferroptosis and dual immunotherapy in orthotopic bladder cancer mouse models.

⚡ 6 min read Read brief →

Aug 2, 2026

Ketogenic Diet Enhances Mebendazole Therapy in Pediatric High-Grade Glioma (Cell Reports Medicine, 2026)

A June 2026 study in Cell Reports Medicine found that a ketogenic diet acts as a metabolic vehicle that enhances mebendazole's anti-tumor effects in juvenile mouse models of high-grade glioma, allowing lower drug doses and improved survival.

⚡ 6 min read Read brief →

Aug 1, 2026 ivermectin

Journal Issues Expression of Concern on the 197-Patient Ivermectin + Mebendazole Study

Anticancer Research flagged the widely-shared Hulscher et al. study (84.4% clinical benefit) with a formal Expression of Concern: no control group, self-reported outcomes. The paper has not been retracted as of August 2026.

⚡ 5 min read Read brief →

Jul 31, 2026

Mebendazole Shows Antiproliferative Activity in Childhood Low-Grade Brain Tumor Models (2026)

A June 2026 preclinical study from Rome found mebendazole significantly inhibited cell growth and migration in two pediatric low-grade glioma cell lines, supporting its potential as a repositioned therapeutic drug.

⚡ 6 min read Read brief →

Jul 28, 2026 fenbendazole

182 Cancer Patients Reported Using Fenbendazole at MD Anderson: ASCO 2026 Survey

A 2026 ASCO abstract documents 182 self-reported fenbendazole users at MD Anderson out of 297,223 visits — with 138 different dosing schedules. A prevalence snapshot with major implications for research design.

⚡ 5 min read Read brief →

Jul 25, 2026

Ivermectin Suppresses Gastric Cancer in Patient-Derived Organoids (2026 Study)

A June 2026 South Korean study found ivermectin suppressed gastric cancer growth in patient-derived 3D organoids, achieving 82.48% cell death when combined with cisplatin — a more realistic tumor model than standard cell lines.

⚡ 6 min read Read brief →

Jul 23, 2026 curcumin

Curcumin Selectively Disrupts Cancer Cell Energy: New 2026 Study (Wrocław University)

A July 2026 study from Wrocław found curcumin cut ATP in fibrosarcoma cells by up to 92% and drove 75% into permanent senescence — outperforming four other natural compounds with the best safety profile.

⚡ 5 min read Read brief →

Jul 18, 2026

PEG-b-PCL Nanocarriers Improve Fenbendazole Delivery to Triple-Negative Breast Cancer Cells (2026)

A June 2026 study from Bulgarian research institutions developed PEG-b-PCL polymer micelles to encapsulate fenbendazole, improving its delivery to triple-negative breast cancer cells — a promising nanoformulation approach at the preclinical stage.

⚡ 5 min read Read brief →

Jul 14, 2026 fenbendazole

ASCO Clinical Notice Against Fenbendazole and Ivermectin: What Patients Need to Know (May 2026)

In May 2026, the American Society of Clinical Oncology issued a formal clinical notice recommending against the use of fenbendazole and ivermectin as cancer treatments. We break down what the notice says — and what the emerging observational data shows.

⚡ 6 min read Read brief →

Jul 9, 2026

Flubendazole + Temozolomide for Glioblastoma: What a 2026 Study Found

A July 2026 study from Charles University found that flubendazole combined with temozolomide reduced glioblastoma cell proliferation and activated apoptosis pathways in three GBM cell lines. Preclinical data only.

⚡ 6 min read Read brief →

Jul 5, 2026 curcumin

Curcumin Nanoformulations 2025–2026: How Nanotechnology Achieves 178× Bioavailability Improvement

Native curcumin has less than 1% oral bioavailability. A 2025–2026 wave of nanocarrier research (PLGA, liposomes, nanomicelles, stimuli-responsive particles) has achieved up to 178× improvement in plasma AUC. Two nanoformulations — Sinacurcumin and Lipocur — are now in Phase I/II cancer trials.

⚡ 7 min read Read brief →

Jul 2, 2026

Ivermectin Outperforms 4 of 5 Chemo Drugs in 2026 Colon Cancer Lab Study

A June 2026 study from UC San Diego found ivermectin combined with recombinant methioninase outperformed four of five first-line chemotherapy drugs against colon cancer cells in vitro, with a chemosensitivity index of 6.7.

⚡ 6 min read Read brief →

Jun 30, 2026

Antiparasitic Drugs in Oncology: 2026 Comprehensive Review (7 Drugs, Multiple Cancers)

A 2026 review from Hamad Medical Corporation and Qatar University synthesizes the anticancer evidence for seven antiparasitic drugs — ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and pyrvinium pamoate — across multiple cancer types.

⚡ 7 min read Read brief →

Jun 26, 2026 Methylene Blue

Methylene Blue 2025–2026: Neuroprotection, Alzheimer's Disease Trials, Senolytic Activity, and Depression Research

2025–2026 research confirms methylene blue as a mitochondrial electron shuttle that bypasses Complex I dysfunction, reduces ROS by 55–65%, inhibits tau aggregation, reduces senescent cells by ~28%, and shows early signal in treatment-resistant depression. Phase 3 Alzheimer's results remain mixed.

⚡ 7 min read Read brief →

Jun 17, 2026 ivermectin

Ivermectin + Mebendazole Show 84.4% Clinical Benefit in 197-Patient Observational Study (Anticancer Research, 2026)

A prospective observational study of 197 cancer patients published in Anticancer Research (2026) found an 84.4% clinical benefit ratio with a compounded ivermectin + mebendazole regimen. Here is a detailed breakdown of the findings.

⚡ 6 min read Read brief →

Jun 8, 2026 curcumin

Curcumin Targets EP300-Driven Glycolysis to Suppress Oral Cancer Growth (Scientific Reports, 2026)

A 2026 study in Scientific Reports identified a specific epigenetic mechanism by which curcumin suppresses oral squamous cell carcinoma (OSCC): by downregulating the histone acetyltransferase EP300, curcumin blocks the Warburg effect in oral cancer cells.

⚡ 6 min read Read brief →

May 30, 2026 Methylene Blue

Methylene Blue in Cancer Research: Photodynamic Therapy and Metabolic Targeting — 2026 Update

2026 reviews and preclinical studies continue to explore methylene blue's dual role as a photodynamic therapy (PDT) sensitizer and metabolic disruptor in cancer cells. Here is a research summary.

⚡ 6 min read Read brief →

May 21, 2026 ivermectin

NCI Initiates Preclinical Investigation of Ivermectin as Potential Anticancer Agent (February 2026)

In February 2026, the National Cancer Institute announced it had begun preclinical laboratory studies to evaluate ivermectin's potential anticancer properties. This is a significant signal from the world's largest cancer research institution.

⚡ 6 min read Read brief →

May 12, 2026 mebendazole

Mebendazole for Glioblastoma: Blood-Brain Barrier Advantage, Johns Hopkins Trial, and the 2025 MBZ+Bumetanide Strategy

Mebendazole crosses the blood-brain barrier — a rare pharmacokinetic advantage for brain tumor drugs. A Johns Hopkins Phase 1 trial confirmed safety at high doses combined with temozolomide. A 2025 study combined MBZ with bumetanide for a dual cytotoxic and anti-invasive effect in glioblastoma.

⚡ 7 min read Read brief →

May 3, 2026 fenbendazole

Fenbendazole Induces Pyroptosis in Breast Cancer via HK2-Caspase-3/GSDME Pathway (Frontiers, 2025)

A 2025 study in Frontiers in Pharmacology traced a precise mechanism: fenbendazole suppresses HK2, triggering caspase-3/GSDME signaling to cause immunogenic pyroptosis in breast cancer cells. Tumor inhibition comparable to cisplatin in mouse xenograft models. Full mechanistic breakdown inside.

⚡ 7 min read Read brief →